Ginkgo Bioworks Holdings Inc vs Hut 8 Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.34 (market cap $505.73M), while Hut 8 Corp trades at $93.12 (market cap $10.94B). The key difference: Hut 8 Corp is far larger — about 21.6× Ginkgo Bioworks Holdings Inc's market cap, and Hut 8 Corp is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | HUT | |
|---|---|---|
Market Cap | $505.73M | $10.94B |
Sector | Health | Technology |
52-Week High | $16.14 | $133.02 |
52-Week Low | $5.48 | $21.37 |
Enterprise Value | $607.68M | $18.38B |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.42, down 3.01% with bearish technical signals. The company reported Q2 2026 revenue of $20M, down 48% year-over-year, while maintaining a high gross margin of 68.04% but significant net losses. Analyst sentiment is mixed with 45% buy ratings amid ongoing business model transition to autonomous laboratory systems and contract research services.
The outlook remains challenging with persistent revenue declines and negative cash flow, though recent earnings beats provide some optimism. Key risks include execution of the business pivot and path to profitability. Wall Street shows cautious optimism with majority buy ratings despite fundamental headwinds.
HUT trades at $91.66, up 7.0% today amid a broader neocloud rally following NVIDIA's $500 billion AI pledge. The stock shows a bearish technical trend with support at $87 and resistance at $92. Fundamentally, Q2 2026 revenue grew 81% year-over-year to $74 million, but net losses widened to -$226 million in 2025. The company is transitioning to an AI data center platform, securing $26.6 billion in contracted backlog and $7.5 billion in project financing.
Outlook is polarized: strong analyst buy consensus (94%) targets $165.11, citing AI infrastructure potential, but high execution risks and persistent losses pose threats. Near-term volatility is likely as the market weighs Beacon Point commercialization progress against earnings misses and negative cash flow from operations.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →